177<\/sup>Lu-PSMA-617 added to standard care prolonged imaging-based progression-free survival and overall survival <\/p>\n<\/h3>\n <\/b><\/p>\n <\/b><\/p>\n TUESDAY, July 6, 2021 (HealthDay News) — Lutetium-177 (177<\/sup>Lu)-prostate-specific membrane antigen (PSMA)-617 radioligand therapy added to standard care is beneficial for patients with advanced PSMA-positive metastatic castration-resistant prostate cancer, according to a study published online June 23 in the New England Journal of Medicine<\/em>.<\/p>\n Oliver Sartor, M.D., from Tulane University in New Orleans, and colleagues conducted an international, phase 3 trial involving patients with metastatic castration-resistant prostate cancer previously treated with at least one androgen receptor-pathway inhibitor and one or two taxane regimens. A total of 831 patients were randomly assigned to receive 177<\/sup>Lu-PSMA-617 plus protocol-permitted standard care, which excluded chemotherapy, immunotherapy, radium-223, and investigational drugs, or standard care alone. Patients were followed for a median of 20.9 months.<\/p>\n The researchers found that compared with standard care, 177<\/sup>Lu-PSMA-617 plus standard care significantly prolonged imaging-based progression-free survival (median, 8.7 versus 3.4 months; hazard ratio for progression or death, 0.40) and overall survival (median, 15.3 versus 11.3 months; hazard ratio for death, 0.62). 177<\/sup>Lu-PSMA-617 was significantly favored for all key secondary end points. A higher incidence of adverse events of grade 3 or above was seen with versus without 177<\/sup>Lu-PSMA-617 (52.7 versus 38.0 percent), while quality of life was not adversely affected.<\/p>\n “The trial aimed to assess the efficacy of 177<\/sup>Lu-PSMA-617 plus standard-care therapies that could safely be combined in order to provide physicians with a broad permitted range of concomitant treatment options,” the authors write.<\/p>\n Several authors disclosed ties to biopharmaceutical companies, including Endocyte, which funded the study.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n